San Diego medical device maker Tandem Diabetes Care recently announced a $60 million public stock offering.

Expected to close Feb. 13, the offering includes 30 million shares of its common stock at a price of $2 per share. In addition, the deal underwriters have a 30-day option to purchase up to 4.5 million additional shares of stock.

Oppenheimer & Co. Inc. is acting as book‐running manager for the offering, with National Securities Corp. as the co-manager.

Tandem Diabetes Care makes touchscreen insulin pumps.

The company in January boosted its manufacturing footprint, including a 50,000-square-foot facility on Barnes Canyon Road becoming fully operational.